Capital A Wealth Management LLC Makes New $596,000 Investment in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Capital A Wealth Management LLC bought a new stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 27,033 shares of the company's stock, valued at approximately $596,000. Teva Pharmaceutical Industries makes up approximately 1.0% of Capital A Wealth Management LLC's holdings, making the stock its 20th biggest holding.

A number of other institutional investors have also recently made changes to their positions in TEVA. B. Riley Wealth Advisors Inc. purchased a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter worth approximately $214,000. Armis Advisers LLC bought a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at about $226,000. Mackenzie Financial Corp grew its holdings in Teva Pharmaceutical Industries by 4.1% in the fourth quarter. Mackenzie Financial Corp now owns 29,889 shares of the company's stock worth $659,000 after purchasing an additional 1,171 shares during the last quarter. Forum Financial Management LP grew its stake in Teva Pharmaceutical Industries by 74.7% during the 4th quarter. Forum Financial Management LP now owns 18,118 shares of the company's stock worth $399,000 after buying an additional 7,748 shares during the last quarter. Finally, Vise Technologies Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $293,000. Institutional investors own 54.05% of the company's stock.

Wall Street Analyst Weigh In

TEVA has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and upped their price target for the company from $21.00 to $23.00 in a research note on Monday, May 12th. UBS Group cut their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research report on Thursday, January 30th. Barclays reduced their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, January 30th. Truist Financial initiated coverage on Teva Pharmaceutical Industries in a research note on Wednesday. They set a "buy" rating and a $25.00 price target on the stock. Finally, Bank of America increased their price objective on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $24.50.

Teva Pharmaceutical Industries Stock Performance

TEVA stock traded up $0.42 during trading on Wednesday, hitting $18.13. 11,474,751 shares of the company traded hands, compared to its average volume of 10,030,688. Teva Pharmaceutical Industries Limited has a 1 year low of $12.47 and a 1 year high of $22.80. The company has a market cap of $20.56 billion, a PE ratio of -12.50, a P/E/G ratio of 1.44 and a beta of 0.62. The stock's 50-day simple moving average is $15.47 and its 200 day simple moving average is $17.36. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The firm had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.99 billion. During the same period in the previous year, the firm earned $0.48 EPS. The business's quarterly revenue was up 1.9% on a year-over-year basis. On average, equities analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.